Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
DPP-IVi

CAROLINA to Strengthen Anti-SU Guidelines

Here is a brief preview of this blast: Today, BI/Lilly presented data from the CAROLINA CVOT (Tradjenta vs Glimepiride) at the ADA 2019 conference. The results demonstrated non-inferiority on 3P-MACE for linagliptin vs. glimepiride (11.8% vs. 12.0%; HR 0.98; p<0.0001) in patients with relatively early T2DM and increased CV risk. Of note, the results signaled no difference in CV safety between both groups, thereby disproving the hypothesis of increased CV risk from glimepiride usage. Recall, in February 2019, BI/Lilly announced that CAROLINA met the primary endpoint of non-inferiority on 3P-MACE. Below, FENIX provides additional thoughts on CAROLINA, potential market dynamics, and implications.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.